Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral inducer of endogenous interferons that acts via the TLR7 pathway. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the potency, safety and tolerability profile of ANA598, which may not be duplicated in future cohorts at higher doses or future clinical studies of longer duration; (ii) the belief that ANA598 is a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV; (iii) the expectation that ANA598 will be active in long-term studies in combination with pegylated interferon and ribavirin and the ability to dose ANA598 for up to 48 weeks in future combination studies; (iv) the ability of Anadys to transition into Phase II studies of ANA598 during 2009; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies (including those described in this press release) may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in future clinical trials, will maintain fast track designation or will receive regulatory approval. In addition, Anadys' results may be affected by risks related to competition from other biotechnology and pharmaceutical companies
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  BC Technical, the nation,s leading non-OEM ... Imaging, a leader in sales, service and installation of ... BC Technical to continue to expand their resources and ... CT modalities. "We are committed to ... Alvarez , president and CEO of BC Technical. "We ...
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)...   Vittamed Corporation , a neurodiagnostics medical device company ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, ... " Teo Forcht Dagi is an ... and venture capital," said Remis Bistras , President and ... clinical, strategic, and entrepreneurial expertise to our Board." ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Va., Jan. 19, 2012 Medicare officials should swiftly authorize ... a new Medicare Part D prescription drug plan if the ... for a "preferred network" plan with inadequate pharmacy access, the ... Since the start of the 2012 plan year on ...
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... medical devices worldwide, today announced that it will participate ... January 23 and 26 in Dubai, United Arab Emirates. ... annual medical exhibition in the Middle East.  Last year, ...
Cached Medicine Technology:Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 3Mindray Medical to Exhibit at Arab Health 2012 in Dubai from January 23-26 2
(Date:8/30/2014)... Aliso Viejo, California (PRWEB) August 30, 2014 ... have announced the release of the TransGhost plugin from ... frightening tool that gives users the ability to tell ... Austin, CEO of Pixel Film Studios. “Users will make ... to use transition plugin.” , With TransGhost users can ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The SI ... nine mobilizations and six muscle energy techniques. Michael P. ... and demonstrates twenty-seven examination techniques for the SI Joint. ... supports Dr. Reiman's live course presentation with North American ... Applying a differential diagnosis approach to ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The KSF ... Challenge and K.Warrior Search on November 8th, 2014 at ... years, these events have introduced many notorious and notable ... Strike-Force, IWF and the UFC. , Among these ... fighters leave its doors armed with the virtues of ...
(Date:8/30/2014)... Saturday 30 August 2014: The first multidisciplinary ... with acute coronary syndromes (ACS) are published today ... paper was written jointly by the European Heart ... (ACCA) and the European Association of Percutaneous Cardiovascular ... Professor Bulent Gorenek (Turkey), chairperson of the task ...
(Date:8/30/2014)... Saturday 30 August 2014: The first recommendations ... in pulmonary embolism are published today in new ... Congress by Professor Stavros V. Konstantinides (Germany/Greece) and ... Guidelines on the diagnosis and management of acute ... Heart Journal (1) and on the ESC Website. ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 2Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 3Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 3Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 4Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2
... April 23 (HealthDay News) -- It goes without saying that ... they can also be very expensive, an expert warns. ... a person bitten by a venomous snake, said Jill Heatley, ... in College Station. The total cost includes hospitalization, which ...
... The International and American Associations for Dental ... in children. These articles, titled "Hypoplasia-Associated Severe Early ... Page Caufield, New York University College of Dentistry) ... (lead author M.E.C. Elfrink, Academic Centre for Dentistry, ...
... destruction of the insulin-producing beta cells. Over 250,000 patients suffer ... daily insulin injections to maintain glucose metabolism. Replacement of the ... organ or isolated human beta cells is the only effective ... of organ donors this method can be offered to only ...
... St. Jude Children,s Research Hospital scientists have rewritten the ... it guards early brain cells from DNA damage. Such ... showed that cells in the developing brain require TopBP1 ... is copied prior to cell division. Investigators also reported ...
... That "brain freeze" headache you experience when eating ice cream ... change in brain blood flow, researchers report. What,s more, ... more troubling forms of headache such as migraine, the U.S. ... blood flow in 13 healthy adults as they sipped ice ...
... April 22 (HealthDay News) -- Tick season has started earlier ... gardeners and others who love the outdoors should take precautions ... People also should keep alert for symptoms of tick-borne ... tick-borne diseases such as Lyme disease, anaplasmosis and babesiosis -- ...
Cached Medicine News:Health News:Cost of Snakebite Therapy May Squeeze Victims' Wallets 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 3Health News:Xenotransplantation as a therapy for type 1 diabetes 2Health News:Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor 2Health News:Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor 3Health News:'Ice Cream Headaches' Might Offer Clues to Migraines 2Health News:Tick Season Starting Early This Year 2
... The Professional Gold Package is ... laboratory. The package includes the ... automated system, starter package accessory ... adapter, specimen mounts 1/2" head, ...
... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
... Plus Sectioning System provides a versatile means ... plant tissues. The 1000 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effects ...
... with a square vice mounting device. ... for mounting specimens and placing in ... blocks are annodized black for easy ... They are shipped three to ...
Medicine Products: